证券代码：688315 证券简称：诺禾致源 公告编号：2025-030 北京诺禾致源科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，北京诺禾致源科技股份有限公司（以下简称"公司" 或"诺禾致源"）股东北京致源禾谷投资管理中心（有限合伙）（以下简称"致源 禾谷"）持有公司 47,106,622 股股份，占公司总股份的 11.32%；北京诺禾禾谷投 资管理中心（有限合伙）（以下简称"诺禾禾谷"）持有公司 12,564,672 股股份， 占公司总股份的 3.02%。上述股份为致源禾谷和诺禾禾谷于公司首次公开发行并 上市前取得的股份，且于 2024 年 4 月 15 日起上市流通。 减持计划的实施结果情况 公司于 2025 年 3 月 20 日在上海证券交易所网站（www.sse.com.cn）披露了 《北京诺禾致源科技股份有限公司股东减持股份计划公告》（公告编号： 2025-006）。致源禾谷和诺禾禾谷计划通过集中竞价、 ...

诺禾致源公告，公司股东致源禾谷和诺禾禾谷的减持计划已实施完毕。截至2025年7月15日，致源禾谷 和诺禾禾谷通过集中竞价交易方式累计减持289.87万股，占公司总股本的0.70%；通过大宗交易方式累 计减持517.9万股，占公司总股本的1.24%。本次减持计划合计减持807.77万股，占公司总股本的 1.94%。减持后，致源禾谷和诺禾禾谷合计持股比例降至12.40%。 ...

Core Viewpoint - The announcement highlights the equity changes of major shareholders in Nuohe Zhiyuan, indicating a reduction in their holdings, which may impact the company's stock performance and investor sentiment [1][2]. Shareholder Equity Changes - Beijing Zhiyuan Hegu Investment Management Center reduced its holdings by 2,077,773 shares (0.50%) through centralized bidding and 2,179,000 shares (0.52%) through block trading, decreasing its ownership from 11.32% to 10.30% [1][2]. - Beijing Nuohe Hegu Investment Management Center reduced its holdings by 217,488 shares (0.05%) through centralized bidding, with no shares sold through block trading, decreasing its ownership from 3.02% to 2.97% [1][2]. Total Shares Reduced - Between April 21, 2025, and June 3, 2025, a total of 4,474,261 shares were sold by both Zhiyuan Hegu and Nuohe Hegu [2]. Company Background - Nuohe Zhiyuan was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 13, 2021, with an initial public offering (IPO) of 40.2 million shares at a price of 12.76 yuan per share, raising a total of 51,295.20 million yuan [2][3]. - The company intended to use the IPO proceeds for projects related to gene sequencing service platform expansion, gene testing reagent research and development, information technology and data center construction, and working capital [2]. Recent Fundraising Activities - In October 2023, Nuohe Zhiyuan announced a private placement of 16 million shares at a price of 20.76 yuan per share, raising a total of 332.16 million yuan, with net proceeds of approximately 327.61 million yuan after deducting issuance costs [3]. - The total fundraising from the IPO and the 2023 private placement amounts to 84,511.2 million yuan [4].

管 理 中 心 1,256.4672 3.02% 1,234.7184 2.97% □大宗交易 / | 证券代码：688315 证券简称：诺禾致源 公告编号：2025-029 | | | --- | --- | | 北京诺禾致源科技股份有限公司 | | | 关于持股 5%以上股东权益变动触及 1%刻度的提示性 | | | 公告 | | | 股东北京致源禾谷投资管理中心（有限合伙）、北京诺禾禾谷投资管理中心（有限 | | | 合伙）及其一致行动人李瑞强保证向本公司提供的信息真实、准确、完整，没有虚假记 | | | 载、误导性陈述或重大遗漏。 | | | 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 | | | 重要内容提示： | | | 权益变动方向 比例增加□ 比例减少? | | | 权益变动前合计比例 65.95% | | | 权益变动后合计比例 64.87% | | | 本次变动是否违反已作出的承诺、意向、计划 是□ 否? | | | 是□ 否? 是否触发强制要约收购义务 | | | 一、 信息披露义务人及其一致行动人的基本信息 | | | ?控股股东/实际控制人及其一致行动人 | ...

Core Viewpoint - The company, Beijing Novogene Technology Co., Ltd., has announced a differentiated cash dividend distribution plan, proposing a cash dividend of RMB 0.05 per share (tax included) for the fiscal year 2024, approved at the annual shareholders' meeting on May 7, 2025 [1][2]. Summary by Sections Dividend Distribution Plan - The company plans to distribute a cash dividend of RMB 0.05 per share to all shareholders, based on the total share capital minus the shares held in the company's repurchase account [2][3]. - As of the announcement date, the total share capital is 416,200,000 shares, with 11,141,468 shares in the repurchase account, resulting in 405,058,532 shares eligible for distribution, totaling approximately RMB 20,252,926.60 (tax included) [2][3]. Ex-Dividend Date and Payment - The ex-dividend date, record date, and cash dividend payment date are specified, with the cash dividend being distributed through the China Securities Depository and Clearing Corporation Limited [3][4]. Tax Implications - For individual shareholders and securities investment funds, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for less than one month, and no tax for shares held over one year [4][5]. - For qualified foreign institutional investors (QFII), a withholding tax of 10% applies, resulting in a net cash dividend of RMB 0.045 per share [5][6]. - Other corporate shareholders are responsible for their own tax declarations, with the gross cash dividend being RMB 0.05 per share [6].

证券代码：688315 证券简称：诺禾致源 公告编号：2025-029 北京诺禾致源科技股份有限公司 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | | □ | 控股股东/实控人 | | | 北京致源禾谷投资管 理中心（有限合伙） | ☑ | 控股股东/实控人的一致 | ☑ 91110105059215524R_ | | | | 行动人 | | | | □ | 其他直接持股股东 | | | 北京诺禾禾谷投资管 | □ | 控股股东/实控人 | 91110108344277089C ☑ | | 理中心（有限合伙） | ☑ | 控股股东/实控人的一致 | | 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | 比例减少☑ | | --- | --- | --- | | 权益变动前合计比例 | 65.95% | | | 权益变动后合计比例 | 64.87% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否☑ | | 是否触发 ...

根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年年度利润分配 预案的议案》，公司拟向全体股东每股派发现金红利 0.05 元（含税）。公司回购专 用证券账户中的股份将不参与公司本次利润分配。截至 2024 年 12 月 31 日，公 司总股本 416,200,000 股，扣减回购专用证券账户中股份数 11,141,468 股，可参 中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 2024 年度差异化分红事项的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）持续督导工作 的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证券发 行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引第 7 号—— 回购股份》等相关规定，对公司 2024 年度差异化分红事项进行了核查，具体情 况如下： 一、差异化分红的原因 2024 年 2 月 5 日，公司召开第三届董事会第十五次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用不低于人民币 8,000 万元（含）， ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-028 北京诺禾致源科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/9 | 2025/6/10 | 2025/6/10 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 7 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （北京诺禾致源科技股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 （2）本次差异化分红送转除权除 ...

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical sector, indicating a positive outlook for investment opportunities in this industry [2]. Core Insights - The pharmaceutical sector has shown resilience with a weekly increase of 1.27%, outperforming the CSI 300 index by 0.16 percentage points, ranking 11th among 31 sectors [7][26]. - The report highlights the potential recovery of the industry due to favorable policies and the gradual rebound of the hospital market, which was previously impacted by anti-corruption measures and centralized procurement [4][26]. - The focus on innovative therapies is expected to drive significant growth, with an emphasis on domestic BIC/FIC innovative drugs showing steady improvement in both quantity and quality [4][26]. Summary by Sections 1. Pharmaceutical Sector Performance - The pharmaceutical sector's weekly performance was +1.27%, with sub-sectors such as Traditional Chinese Medicine II (+1.73%), Medical Services (+1.45%), and Chemical Pharmaceuticals (+1.44%) showing notable gains [7][26]. 2. Key Company Ratings - Companies such as Aosaikang (002755.SZ) and Cloudtop New Medicine (01952.HK) received "Buy" ratings, while Renfu Pharmaceutical (600079.SH) and Dize Pharmaceutical (688192.SH) were rated as "Hold" [1][4]. 3. Notable Industry News - BeiGene initiated a head-to-head Phase III clinical trial for BGB-16673, a targeted BTK PROTAC drug, which has shown promising results in earlier trials [26][27]. - AbbVie received FDA approval for its c-Met targeted ADC drug, marking a significant milestone in the ADC product line [29][30]. 4. Investment Recommendations - The report recommends focusing on high-quality targets within the formulation sector, particularly companies with efficient management and strong product pipelines, such as Aosaikang and Dize Pharmaceutical [4][26].

Core Viewpoint - The IVD industry is experiencing a significant downturn in revenue and profits, with over 70% of companies reporting a year-on-year decline in revenue and more than half facing losses or drastically reduced profits [2][5]. Revenue and Profit Trends - In Q1 2025, major IVD companies such as Mindray Medical, Dian Diagnostics, and RunDa Medical reported substantial declines in both revenue and net profit, with Mindray's revenue at 8.237 billion yuan (down 12.12%) and net profit at 2.629 billion yuan (down 16.81%) [2][4]. - Among 60 IVD companies analyzed, 16 reported revenue growth, with 8 achieving both revenue and net profit growth [2]. Market Challenges - The IVD sector is facing multiple challenges, including a slowdown in the conventional medical testing market, stricter cost control policies in healthcare, and the impact of centralized procurement policies [5][6]. - The anticipated centralized procurement in 28 provinces is expected to further pressure IVD companies, particularly in the high-volume chemical luminescence market [6]. Company Strategies and Innovations - Some companies are adapting by focusing on niche markets and innovative product offerings, such as New Industry and Sansure Bio, which reported revenue growth of 10.12% and 21.62% respectively in Q1 2025 [9]. - Companies are also exploring international markets, with Mindray's overseas revenue reaching 16.43 billion yuan in 2024, accounting for 44.75% of total revenue [9][10]. Technological Advancements - The IVD industry is witnessing a shift towards digitalization and AI integration, with partnerships like that of BGI and Dian Diagnostics aiming to enhance diagnostic efficiency and precision [10][11]. - The emergence of AI technologies is reshaping the IVD landscape, although challenges remain in data integration and commercialization [11].